Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis

Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis

Colorectal peritoneal metastases (CPM) are the third most common site of metastatic spread of colorectal cancer and are associated with worse survival than other sites of metastatic disease. In recent years tumoral circulating tumoral DNA (ctDNA) mutational status has been increasingly utilized in c...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael G. White, Reed I. Ayabe, Mohammad A. Zeineddine, Fadl A. Zeineddine, Abdelrahman M.G. Yousef, Mahmoud Yousef, Norman J. Galbraith, J․Bryan Iorgulescu, Christopher Scally, Keith Fournier, Timothy E. Newhook, Nancy Y. You, Jason Willis, Scott Kopetz, George J. Chang, John Paul Shen, Abhineet Uppal
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Translational Oncology
Subjects:
Colorectal cancer
Circulating tumoral DNA
Peritoneal metastasis
Liver metastasis
BRAF mutation
KRAS mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S193652332500110X
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal peritoneal metastases (CPM) are the third most common site of metastatic spread of colorectal cancer and are associated with worse survival than other sites of metastatic disease. In recent years tumoral circulating tumoral DNA (ctDNA) mutational status has been increasingly utilized in clinical decision making for metastatic colorectal cancer patients despite its utility in CPM being poorly understood. Here we describe standard of care performed mutational profiles and associated outcomes for unresectable CPM patients, with a contextual comparison to 160 unresected colorectal liver metastases (CLM) patients. Of 508 patients, 288 (57 %) had CPM alone and 220 (43 %) had CPM with extraperitoneal metastases. Patients with synchronous CPM and CLM had worse overall survival (HR 1.67 [95 %CI 1.26–2.22]). Mutations in ctDNA were noted in 110/145 (75.9 %) of CPM patients, with mutations in KRAS or PIK3CA ctDNA being associated with worse survival. Importantly, the association between tumoral mutational profile and survival differed by site of metastatic disease. The prognostic significance of specific mutations, particularly BRAF and KRAS, differs between patients with CPM and CLM, and supports the distinct biology of these metastatic sites and the importance of tissue and circulating genomic profiling to risk-stratify these patients according to site of metastasis.
ISSN:1936-5233

Similar Items